Pictet Asset Management Holding SA Has $17.46 Million Holdings in Teva Pharmaceutical Industries Ltd. $TEVA

Pictet Asset Management Holding SA boosted its stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 4.2% in the first quarter, HoldingsChannel reports. The firm owned 580,428 shares of the company’s stock after acquiring an additional 23,156 shares during the period. Pictet Asset Management Holding SA’s holdings in Teva Pharmaceutical Industries were worth $17,461,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Norges Bank bought a new position in Teva Pharmaceutical Industries during the fourth quarter worth about $1,098,060,000. Harel Insurance Investments & Financial Services Ltd. raised its position in shares of Teva Pharmaceutical Industries by 19.2% in the 4th quarter. Harel Insurance Investments & Financial Services Ltd. now owns 44,951,773 shares of the company’s stock valued at $1,402,945,000 after acquiring an additional 7,255,083 shares during the period. Wellington Management Group LLP raised its position in shares of Teva Pharmaceutical Industries by 39,228.4% in the 3rd quarter. Wellington Management Group LLP now owns 6,895,838 shares of the company’s stock valued at $139,296,000 after acquiring an additional 6,878,304 shares during the period. Clal Insurance Enterprises Holdings Ltd raised its position in shares of Teva Pharmaceutical Industries by 18.8% in the 4th quarter. Clal Insurance Enterprises Holdings Ltd now owns 37,404,106 shares of the company’s stock valued at $1,171,378,000 after acquiring an additional 5,917,423 shares during the period. Finally, Schroder Investment Management Group boosted its stake in Teva Pharmaceutical Industries by 261.1% during the 4th quarter. Schroder Investment Management Group now owns 7,426,885 shares of the company’s stock worth $231,793,000 after acquiring an additional 5,370,253 shares during the last quarter. Institutional investors own 54.05% of the company’s stock.

Insider Buying and Selling

In related news, EVP Eliyahu Sharon Kalif sold 153,251 shares of the firm’s stock in a transaction on Thursday, May 14th. The shares were sold at an average price of $35.61, for a total transaction of $5,457,268.11. Following the sale, the executive vice president directly owned 172,184 shares in the company, valued at $6,131,472.24. This trade represents a 47.09% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Christine Fox sold 21,258 shares of the business’s stock in a transaction on Thursday, April 30th. The shares were sold at an average price of $35.31, for a total transaction of $750,619.98. Following the completion of the sale, the executive vice president directly owned 63,647 shares in the company, valued at $2,247,375.57. This represents a 25.04% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 465,931 shares of company stock valued at $16,332,989. 0.54% of the stock is owned by corporate insiders.

Analyst Ratings Changes

TEVA has been the subject of a number of analyst reports. Wall Street Zen upgraded shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a report on Saturday, June 6th. UBS Group increased their target price on shares of Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the stock a “buy” rating in a report on Thursday, April 30th. Barclays lifted their price target on shares of Teva Pharmaceutical Industries from $38.00 to $40.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a report on Monday, April 20th. Finally, Bank of America upped their price objective on shares of Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the company a “buy” rating in a research report on Thursday, April 9th. Nine analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Teva Pharmaceutical Industries currently has an average rating of “Moderate Buy” and an average price target of $41.78.

Teva Pharmaceutical Industries Price Performance

Shares of TEVA opened at $34.55 on Friday. The company has a debt-to-equity ratio of 1.70, a quick ratio of 0.78 and a current ratio of 1.01. The stock has a 50 day simple moving average of $33.89 and a 200 day simple moving average of $32.54. Teva Pharmaceutical Industries Ltd. has a 52-week low of $14.99 and a 52-week high of $37.35. The firm has a market capitalization of $39.73 billion, a PE ratio of 25.98, a P/E/G ratio of 4.08 and a beta of 0.86.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its earnings results on Tuesday, March 31st. The company reported $0.53 earnings per share (EPS) for the quarter. The business had revenue of $3.98 billion during the quarter. Teva Pharmaceutical Industries had a return on equity of 43.53% and a net margin of 9.01%. Sell-side analysts predict that Teva Pharmaceutical Industries Ltd. will post 1.97 EPS for the current fiscal year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.